Mark Moasser, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-353-7070
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Tufts University, Boston, MAM.D.1988School of Medicine
    University of Pennsylvania, Philadelphia, PAB.A.1984Biophysics, Music
    New York Hospital - Cornell Medical Center, New York, NYResidency1991Internal Medicine
    Memorial Sloan-Kettering Cancer Center, New York, NYFellowship1995Medical Oncology

    Collapse Overview 
    Collapse Overview
    Physician-scientist seeking to understand the molecular basis of cancers, particularly oncogene-driven cancers, and to translate this knowledge into highly effective treatments for cancer.

    Collapse Research 
    Collapse Research Activities and Funding
    Development of first-in-class HER3 inhibitors
    UCSF Clinical and Translational Sciences Institute Catalyst 000000Apr 10, 2017 - Oct 9, 2018
    Role: PI, with coPI Jack Taunton
    A next-generation approach for inactivation of the HER2-HER3 tumor driver
    BCRF-AACR 218084Sep 1, 2012 - Aug 31, 2014
    Role: Principal Investigator
    Role Description: with David Agard
    Understanding the adaptational network underlying HER3 addiction
    California Breast Cancer Research Program 18IB-0030Aug 1, 2012 - Jul 31, 2013
    Role: Principal Investgator
    Towards highly effective inactivation of HER2-HER3 signaling
    California Breast Cancer Research Program 16OB-0150Jul 1, 2010 - Jun 30, 2014
    Role: Principal Investigator
    Breaking the HER3 barrier in the treatment of HER2-amplified breast cancer
    Mary Kay Ash Charitable Foundation Mary Kay Ash Charitable FoundationDec 1, 2009 - Nov 30, 2011
    Role: Principle Investigator
    An integrated approach towards the eradication of HER2-driven breast cancer
    Susan G. Komen Foundation KG081684Jan 22, 2008 - Jan 21, 2010
    Role: Principal Investigator
    Role Description: with John Kuriyan & Jim Wells
    Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity
    NIH R21CA121108Jan 1, 2007 - Dec 31, 2009
    Role: Principal Investigator
    Understanding resistance in the HER2-HER3 tumor drive
    NIH R01CA122216Jul 1, 2006 - May 31, 2019
    Role: PI
    Anatomic and Biologic Staging of Breast Disease with MRI
    NIH/NCI R01 CA069587Apr 1, 2006 - Nov 30, 2011
    Role: co-investigator
    HER3 infidelity and resistance to tyrosine kinase inhibitors
    California Breast Cancer Research Program 11IB-0069Aug 1, 2005 - Jun 30, 2007
    Role: Principal Investigator
    Promiscuous HER3 signaling; A new target in the treatment of breast cancer
    Susan G. Komen Foundation BCTR0504177May 1, 2005 - Apr 30, 2008
    Role: Principal Investigator
    Adhesion signaling by a novel mitotic substrate of src
    NIH R01CA113952Apr 1, 2005 - Feb 28, 2011
    Role: Principal Investigator
    Model-based predictions of responses to RTK pathway therapies
    National Institutes of Health U54 CA112970Sep 30, 2004 - Feb 28, 2015
    Role: PI on sub-project
    Model-based predictions of responses to RTK pathway therapies
    NIH/NCI U54 CA112970Sep 30, 2004 - Feb 28, 2015
    Role: Co-investigator
    A novel mitotic phosphoprotein associated with src kinases
    American Cancer Society RSG-02-139-01-CDDJul 1, 2002 - Jun 30, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Sci Rep. 2021 Apr 27; 11(1):9091. Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM. PMID: 33907275.
      View in: PubMed   Mentions:    Fields:    
    2. Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain. Mol Cancer Res. 2021 Jun; 19(6):957-967. Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer CA, Spassov DS, Oses-Prieto J, Burlingame A, Moasser MM. PMID: 33727342.
      View in: PubMed   Mentions:    Fields:    
    3. Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. Biochem Pharmacol. 2021 01; 183:114317. Kazemi S, Kawaguchi S, Badr CE, Mattos DR, Ruiz-Saenz A, Serrill JD, Moasser MM, Dolan BP, Paavilainen VO, Oishi S, McPhail KL, Ishmael JE. PMID: 33152346.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expr Purif. 2021 Mar; 179:105780. Abdel Aziz MH, Fan Y, Liu L, Moasser MM, Fu H, Jura N, Arkin MR. PMID: 33115654.
      View in: PubMed   Mentions:    Fields:    
    5. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    6. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Ka/d and HDAC. J Invest Dermatol. 2021 Feb; 141(2):364-373. Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. PMID: 32603749.
      View in: PubMed   Mentions: 3     Fields:    
    7. HER family in cancer progression: From discovery to 2020 and beyond. Adv Cancer Res. 2020; 147:109-160. Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM. PMID: 32593399.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    8. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nat Cell Biol. 2019 06; 21(6):778-790. Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ. PMID: 31160710.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    9. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell Rep. 2018 10 09; 25(2):449-463.e4. Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. PMID: 30304684.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    10. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 2018 07 01; 78(13):3645-3658. Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. PMID: 29760043.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    11. Regulation of inside-out ß1-integrin activation by CDCP1. Oncogene. 2018 05; 37(21):2817-2836. Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. PMID: 29511352.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    12. Targeting HER2 by Combination Therapies. J Clin Oncol. 2018 03 10; 36(8):808-811. Ruiz-Saenz A, Moasser MM. PMID: 29381433.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    14. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6912-E6921. Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. PMID: 28760953.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    15. Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Cell Chem Biol. 2017 07 20; 24(7):917. Littlefield P, Moasser MM, Jura N. PMID: 28732202.
      View in: PubMed   Mentions:    Fields:    
    16. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    17. Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin. Breast Cancer Res Treat. 2016 Feb; 155(3):431-40. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. PMID: 26860947.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    18. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015 Dec 01; 6(38):41123-33. Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. PMID: 26516700.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    19. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Nov; 1(8):1154-61. Moasser MM, Krop IE. PMID: 26204261.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    20. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. . 2015 Dec; 14(12):2805-17. Amin DN, Ahuja D, Yaswen P, Moasser MM. PMID: 26438156.
      View in: PubMed   Mentions:
    21. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10(4):e0121607. Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. PMID: 25901353.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive. Clin Cancer Res. 2015 Jul 01; 21(13):2886-8. Campbell MR, Moasser MM. PMID: 25609069.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    23. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. PMID: 25605863.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    24. A multilevel model of postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2078-92. Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH. PMID: 25017248.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    25. Two dimensions in targeting HER2. J Clin Oncol. 2014 Jul 01; 32(19):2074-7. Moasser MM. PMID: 24868026.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    26. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    27. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol. 2014 04 24; 21(4):453-458. Littlefield P, Moasser MM, Jura N. PMID: 24656791.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    28. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 01; 73(3):1168-79. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. PMID: 23243018.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    29. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 01; 447(3):417-25. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. PMID: 22853430.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    30. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011 Apr 29; 6(4):e19154. Spassov DS, Ahuja D, Wong CH, Moasser MM. PMID: 21559459.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    31. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. . 2011 Apr 15; 10(8):1225-32. Spassov DS, Wong CH, Moasser MM. PMID: 21490433.
      View in: PubMed   Mentions:
    32. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. PMID: 21350003.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    33. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. PMID: 21189288.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    34. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50. Amin DN, Campbell MR, Moasser MM. PMID: 20816829.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    35. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 01; 16(5):1373-83. Campbell MR, Amin D, Moasser MM. PMID: 20179223.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansAnimalsCells
    36. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. PMID: 20371474.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansAnimalsCells
    37. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    38. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. PMID: 19349359.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    39. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 01; 15(7):2311-22. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. PMID: 19318475.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    40. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. PMID: 19047117.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    41. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76. Arkin M, Moasser MM. PMID: 19037833.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    42. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 01; 415(1):97-110. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. PMID: 18498248.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    43. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. Chien AJ, Moasser MM. PMID: 18410794.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    44. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. PMID: 17968965.
      View in: PubMed   Mentions: 14     Fields:    Translation:Animals
    45. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007 Dec; 13(12):527-34. Sergina NV, Moasser MM. PMID: 17981505.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    46. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25; 445(7126):437-41. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. PMID: 17206155.
      View in: PubMed   Mentions: 387     Fields:    Translation:Cells
    47. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006 Jul; 54(7):1119-24. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. PMID: 16866685.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    48. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006 Jun; 54(6):925-31. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. PMID: 16776787.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    49. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006 Aug; 98(3):343-8. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. PMID: 16541322.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    50. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005 Aug 11; 24(34):5333-43. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. PMID: 16007225.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    51. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005 Apr; 6(1):55-60. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. PMID: 15899073.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    52. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar; 90(2):157-63. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. PMID: 15803362.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    53. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4062-7. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. PMID: 15217939.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    54. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. . 2004 Jun; 3(6):796-803. Mizenina OA, Moasser MM. PMID: 15136770.
      View in: PubMed   Mentions:
    55. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003 Oct 01; 9(12):4340-6. She QB, Solit D, Basso A, Moasser MM. PMID: 14555504.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCells
    56. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr; 9(4):1267-73. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. PMID: 12684394.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    Mark's Networks
    Concepts (305)
    Derived automatically from this person's publications.
    _
    Co-Authors (58)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _